Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Archives of pharmacal research

• Publication date

  2026-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12272-026-01595-zPMID 41656479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy

  2025cited by this paper
• Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity.

  2025cited by this paper
• Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study.

  2025cited by this paper
• A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

  2025cited by this paper
• Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

  2025influential reference
• JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials.

  2025cited by this paper
• CD63 as a potential biomarker for patients with ovarian cancer.

  2025cited by this paper
• CD47 inhibits phagocytosis through Vav dephosphorylation.

  2025cited by this paper
• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

  2025cited by this paper
• Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate

  2025cited by this paper
• Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification

  2025cited by this paper
• SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer

  2025cited by this paper
• SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

  2025cited by this paper
• Correction: Xiao et al. Mechanism of P-Hydroxy Benzyl Alcohol Against Cerebral Ischemia Based on Metabonomics Analysis. Int. J. Mol. Sci. 2025, 26, 317

  2025cited by this paper
• Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

  2025influential reference
• Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.

  2025influential reference
• Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.

  2025cited by this paper
• Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

  2024cited by this paper
• A pivotal decade for bispecific antibodies?

  2024cited by this paper
• The present and future of bispecific antibodies for cancer therapy

  2024cited by this paper
• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

  2024cited by this paper
• Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study

  2024cited by this paper
• EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells

  2024cited by this paper
• SMARCA4-deficient central nervous system metastases: A case series and systematic review.

  2024cited by this paper
• EGFR-directed antibodies promote HER2 ADC internalization and efficacy

  2024cited by this paper
• BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.

  2024cited by this paper
• A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.

  2024cited by this paper
• Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.

  2024cited by this paper
• DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

  2024cited by this paper
• Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

  2024cited by this paper
• Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala-Ala as the optimal dipeptide.

  2024cited by this paper
• Inotuzumab Ozogamicin: First Pediatric Approval

  2024cited by this paper
• A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers

  2024cited by this paper
• Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

  2024cited by this paper
• A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer

  2024cited by this paper
• Heterogeneity of late endosome/lysosomes shown by multiplexed DNA-PAINT imaging

  2024cited by this paper
• Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8+CD69+ T cells

  2024cited by this paper
• Evaluation of Double Self-Immolative Linker-Based Antibody-Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential.

  2024cited by this paper
• Serum Exosomes Expressing CD9, CD63 and HER2 From Breast-Cancer Patients Decreased After Surgery of the Primary Tumor: A Potential Biomarker of Tumor Burden

  2024cited by this paper
• Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma

  2024cited by this paper
• Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

  2024cited by this paper
• FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

  2024cited by this paper
• TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

  2024cited by this paper
• Designed endocytosis-inducing proteins degrade targets and amplify signals

  2024cited by this paper
• A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

  2024cited by this paper
• FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.

  2024cited by this paper
• Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

  2024influential reference
• On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy.

  2024cited by this paper
• RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

  2024cited by this paper
• Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

  2024cited by this paper
• Sacituzumab Govitecan (Trodelvy)

  2024cited by this paper
• Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?

  2024cited by this paper
• Payload diversification: a key step in the development of antibody–drug conjugates

  2023cited by this paper
• Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

  2023influential reference
• Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

  2023cited by this paper
• Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

  2023cited by this paper
• A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval

  2023cited by this paper
• Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates.

  2023cited by this paper
• Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY-Breast01).

  2023cited by this paper
• Mirvetuximab Soravtansine: First Approval

  2023cited by this paper
• SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

  2023cited by this paper
• Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor

  2023influential reference
• Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

  2023cited by this paper
• Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.

  2023influential reference
• Antibody drug conjugates beyond cytotoxic payloads.

  2023cited by this paper
• Future potential targets of antibody-drug conjugates in breast cancer.

  2023cited by this paper
• Antibody-drug conjugate [ADC] treatment of leukaemia.

  2023cited by this paper
• Revisiting the Role of CD63 as Pro‐Tumorigenic or Anti‐Tumorigenic Tetraspanin in Cancers and its Theragnostic Implications

  2023cited by this paper
• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

  2023cited by this paper
• Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies

  2023cited by this paper
• New Life of Topoisomerase I Inhibitors as Antibody Drug Conjugate Warheads.

  2023cited by this paper
• Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

  2023cited by this paper
• NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects

  2023cited by this paper
• An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates.

  2022cited by this paper
• Opportunities and challenges of bi-specific antibodies.

  2022cited by this paper
• Antibody-Drug Conjugates Containing Payloads from Marine Origin

  2022cited by this paper
• Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

  2022cited by this paper
• Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

  2022cited by this paper
• Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.

  2022cited by this paper
• Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate.

  2022cited by this paper
• Late outcomes of the frozen elephant trunk technique for acute and chronic aortic dissection: the angle change of the FROZENIX by “spring-back” force

  2022cited by this paper
• Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low.

  2022cited by this paper
• The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.

  2022cited by this paper
• Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

  2022cited by this paper
• A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity.

  2022cited by this paper
• Enfortumab Vedotin (Padcev)

  2022cited by this paper
• The therapeutic window of antibody drug conjugates: A dogma in need of revision.

  2022cited by this paper
• Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

  2022cited by this paper
• A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes

  2022cited by this paper
• DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

  2022cited by this paper
• More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

  2022cited by this paper
• Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies

  2022cited by this paper
• Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy.

  2021cited by this paper
• Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.

  2021cited by this paper
• Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker.

  2021cited by this paper
• Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates

  2021cited by this paper
• Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

  2021cited by this paper
• Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation.

  2021influential reference
• Roles of MET in Human Cancer.

  2021cited by this paper
• LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinson’s disease and dementia with Lewy bodies

  2021cited by this paper

• No citing papers are available for this paper.